Literature DB >> 22434049

Functional imaging techniques in hepatocellular carcinoma.

V Goh1, D Sarker, S Osmany, G J R Cook.   

Abstract

Novel biological therapies, including tyrosine kinase inhibitors such as sorafenib, improve the survival of patients with unresectable hepatocellular carcinoma. However, assessment of therapeutic efficacy remains challenging with conventional imaging techniques such as ultrasonography, CT or MRI that predominantly rely on size change to detect a treatment response. A beneficial tumour effect may go unrecognized in some patients who do not show tumour shrinkage and conversely, some patients may be maintained on treatment that is not active. This paper explores the use of functional imaging methods that are showing promise in the assessment of hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2012        PMID: 22434049     DOI: 10.1007/s00259-012-2096-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  60 in total

1.  Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).

Authors:  Tao Jiang; Avinash Kambadakone; Naveen M Kulkarni; Andrew X Zhu; Dushyant V Sahani
Journal:  Invest Radiol       Date:  2012-01       Impact factor: 6.016

2.  Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling.

Authors:  Tong San Koh; Choon Hua Thng; Septian Hartono; Puor Sherng Lee; Su Pin Choo; Donald Y H Poon; Han Chong Toh; Sotirios Bisdas
Journal:  Eur Radiol       Date:  2009-01-10       Impact factor: 5.315

3.  Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

Authors:  Julien Edeline; Eveline Boucher; Yan Rolland; Elodie Vauléon; Marc Pracht; Christophe Perrin; Catherine Le Roux; Jean-Luc Raoul
Journal:  Cancer       Date:  2011-06-28       Impact factor: 6.860

4.  Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor.

Authors:  Davide Ippolito; Pietro-Andrea Bonaffini; Laura Ratti; Laura Antolini; Rocco Corso; Ferruccio Fazio; Sandro Sironi
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

5.  A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.

Authors:  Joong-Won Park; Ji Hoon Kim; Seok Ki Kim; Keon Wook Kang; Kyung Woo Park; Jun-Il Choi; Woo Jin Lee; Chang-Min Kim; Byung Ho Nam
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

6.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.

Authors:  Chi-Lai Ho; Simon C H Yu; David W C Yeung
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

7.  Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography.

Authors:  Yu Xia; Masatoshi Kudo; Yasunori Minami; Kinuyo Hatanaka; Kazuomi Ueshima; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Shunsuke Takahashi; Chie Tatsumi; Taisuke Ueda; Sosuke Hayaishi; Kiyoshi Maekawa
Journal:  Oncology       Date:  2008-12-17       Impact factor: 2.935

8.  Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study.

Authors:  Kyung Hoon Hwang; Duck-Joo Choi; Sang-Yoon Lee; Min Kyung Lee; Wonsick Choe
Journal:  Appl Radiat Isot       Date:  2009-02-20       Impact factor: 1.513

9.  PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline.

Authors:  N Salem; Y Kuang; F Wang; G T Maclennan; Z Lee
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-11-28       Impact factor: 2.346

10.  Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Guang Chen; Da-Qing Ma; Wen He; Bao-Feng Zhang; Li-Qin Zhao
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

View more
  11 in total

Review 1.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

2.  Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

Authors:  Egesta Lopci; Guido Torzilli; Dario Poretti; Lauro J Souza de Neto; Matteo Donadon; Lorenza Rimassa; Ezio Lanza; Juliano Guerra Sabongi; Roberto Ceriani; Nicola Personeni; Angela Palmisano; Vittorio Pedicini; Tiziana Comito; Marta Scorsetti; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-12       Impact factor: 9.236

3.  Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Francesco Bertagna; Mattia Bertoli; Giovanni Bosio; Giorgio Biasiotto; Ramin Sadeghi; Raffaele Giubbini; Giorgio Treglia
Journal:  Hepatol Int       Date:  2014-09-03       Impact factor: 6.047

4.  Imaging for assessment of treatment response in hepatocellular carcinoma: Current update.

Authors:  Koichi Hayano; Sang Ho Lee; Dushyant V Sahani
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun

5.  X-ray Scatter Imaging of Hepatocellular Carcinoma in a Mouse Model Using Nanoparticle Contrast Agents.

Authors:  Danielle Rand; Zoltan Derdak; Rolf Carlson; Jack R Wands; Christoph Rose-Petruck
Journal:  Sci Rep       Date:  2015-10-29       Impact factor: 4.379

6.  STAT1-induced regulation of lncRNA ZFPM2-AS1 predicts poor prognosis and contributes to hepatocellular carcinoma progression via the miR-653/GOLM1 axis.

Authors:  Xi-Wu Zhang; Qiu-Han Li; Zuo-di Xu; Jin-Jin Dou
Journal:  Cell Death Dis       Date:  2021-01-04       Impact factor: 8.469

7.  Long non-coding RNA SNHG22 facilitates hepatocellular carcinoma tumorigenesis and angiogenesis via DNA methylation of microRNA miR-16-5p.

Authors:  Yinxin Zhang; Changliang Lu; Haiwei Cui
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Assessment of hemodynamics in a rat model of liver cirrhosis with precancerous lesions using multislice spiral CT perfusion imaging.

Authors:  Guolin Ma; Rongjie Bai; Huijie Jiang; Xuejia Hao; Zaisheng Ling; Kefeng Li
Journal:  Biomed Res Int       Date:  2013-06-20       Impact factor: 3.411

9.  Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.

Authors:  Natsuhiko Shirota; Kazuhiro Saito; Katsutoshi Sugimoto; Kenichi Takara; Fuminori Moriyasu; Koichi Tokuuye
Journal:  Cancer Imaging       Date:  2016-01-29       Impact factor: 3.909

10.  68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma.

Authors:  Hao Wang; Wenwei Zhu; Shuhua Ren; Yanyan Kong; Qi Huang; Jun Zhao; Yihui Guan; Huliang Jia; Jinhong Chen; Lu Lu; Fang Xie; Lunxiu Qin
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.